Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

The difference in the proportion of del(1p32) or del(1p32) with 1q21 gains was higher in secondary EMM but did not reach statistical significance (del(1p32) (28.6% (16/56) vs. 20.7% (23/111); p = 0.33) and del(1p32) + 1q21 gains (87.5% (14/16) vs. 60.9% (14/23); p = 0.086)).

also in 111,027 other papers